



December 22, 2022

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Sirs,

**Sub: Receipt of AUD 94 million on account of deferred consideration on the sale of the Company's Australian operations in 2019**

We would like to inform you that Strides Pharma Global Pte Limited, a step-down subsidiary of the Company in Singapore, has received AUD 94 Million as the deferred consideration for the sale of the Company's Australian operations in 2019. The proceeds will be utilized for deleveraging the balance sheet.

Strides, in 2019, exited its investments in Australia for AUD 394 million. The company received AUD 300 million immediately on the transaction's closing, and the same was used towards significant deleveraging of the balance sheet through repayment of debt. The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument.

Strides continues to be a preferred supplier to Arrotex, which is the largest generic company in Australia.

We request that you take the above on record.

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com